LENTINI, Giovanni
 Distribuzione geografica
Continente #
NA - Nord America 11.082
EU - Europa 2.865
AS - Asia 1.012
SA - Sud America 14
OC - Oceania 13
AF - Africa 5
Continente sconosciuto - Info sul continente non disponibili 4
Totale 14.995
Nazione #
US - Stati Uniti d'America 11.067
CN - Cina 880
SE - Svezia 807
UA - Ucraina 565
IT - Italia 494
DE - Germania 374
FI - Finlandia 281
GB - Regno Unito 143
FR - Francia 90
IN - India 44
BE - Belgio 34
IE - Irlanda 34
VN - Vietnam 25
IR - Iran 16
CA - Canada 14
SG - Singapore 14
NL - Olanda 12
AU - Australia 8
ID - Indonesia 8
RU - Federazione Russa 7
BR - Brasile 6
LV - Lettonia 6
NZ - Nuova Zelanda 5
EU - Europa 4
JP - Giappone 4
CL - Cile 3
KR - Corea 3
NO - Norvegia 3
RO - Romania 3
TR - Turchia 3
BO - Bolivia 2
CH - Svizzera 2
EE - Estonia 2
EG - Egitto 2
ES - Italia 2
HK - Hong Kong 2
MY - Malesia 2
SA - Arabia Saudita 2
TH - Thailandia 2
BD - Bangladesh 1
BN - Brunei Darussalam 1
CZ - Repubblica Ceca 1
EC - Ecuador 1
FK - Isole Falkland (Malvinas) 1
GE - Georgia 1
GR - Grecia 1
HR - Croazia 1
HU - Ungheria 1
IL - Israele 1
KH - Cambogia 1
LU - Lussemburgo 1
MA - Marocco 1
MX - Messico 1
PH - Filippine 1
PL - Polonia 1
RE - Reunion 1
TW - Taiwan 1
VE - Venezuela 1
ZA - Sudafrica 1
Totale 14.995
Città #
Fairfield 1.325
Jacksonville 1.311
Chandler 1.229
Woodbridge 965
Houston 696
Ashburn 642
Nyköping 599
Cambridge 529
Seattle 500
Wilmington 452
Ann Arbor 406
Roxbury 298
Lawrence 294
Nanjing 292
Des Moines 192
New York 181
Princeton 166
Beijing 138
Bari 137
Boardman 129
Hebei 73
San Diego 73
Shenyang 70
Nanchang 69
Brooklyn 68
Inglewood 66
Jiaxing 51
Dearborn 44
Dublin 34
Pune 34
Brussels 33
Changsha 31
Tianjin 31
London 28
Paris 25
Dong Ket 24
Redwood City 24
Jinan 23
Rome 23
Marseille 19
San Mateo 19
Falls Church 16
Leawood 16
Zhengzhou 15
Ardabil 14
Hefei 14
Helsinki 13
Norwalk 13
San Francisco 13
Washington 13
Ningbo 11
Auburn Hills 10
Toronto 10
Augusta 9
Milan 9
Guangzhou 8
Kilburn 8
Bologna 7
Hangzhou 7
Los Angeles 7
Indiana 6
Kansas City 6
Mumbai 6
Taizhou 6
Auckland 5
Bitonto 5
Catania 5
Frankfurt am Main 5
Melbourne 5
Monmouth Junction 5
Triggiano 5
Acquaviva delle Fonti 4
Chicago 4
Florence 4
Kunming 4
Naples 4
Noci 4
Palermo 4
Riga 4
Siena 4
Tappahannock 4
Belém 3
Chatsworth 3
Chengdu 3
Council Bluffs 3
Fuzhou 3
Islington 3
Kiev 3
Oslo 3
Prescot 3
Redmond 3
Santeramo in Colle 3
Selargius 3
Stockholm 3
Termoli 3
Turi 3
Adelfia 2
Amsterdam 2
Ancona 2
Arnesano 2
Totale 11.708
Nome #
Acidi carbossilici derivati dell'antracene e suoi isosteri: effetti sulla conduttanza al cloro 126
Positional isomers of mannose-quinoline conjugates and their copper complexes: Exploring the biological activity 115
A convenient synthesis of lubeluzole and its enantiomer: Evaluation as chemosensitizing agents on human ovarian adenocarcinoma and lung carcinoma cells 114
Antioxidant Activity of Uva di Troia Canosina: Comparison of Two Extraction Methods 113
Plant-derived anticancer agents: Lessons from the pharmacology of geniposide and its aglycone, genipin 113
The chemistry and pharmacology of citrus limonoids 108
Antimicrobial and antibiofilm activities of citrus water-extracts obtained by microwave-assisted and conventional methods 105
A Mini-Review on Thalidomide: Chemistry, Mechanisms of Action, Therapeutic Potential and Anti-Angiogenic Properties in Multiple Myeloma 105
Synthesis and evaluation of berberine derivatives and analogs as potential antiacetylcholinesterase and antioxidant agents 104
Increased rigidity of the chiral centre of tocainide favours stereoselectivity and use-dependent block of skeletal muscle Na+ channels enhancing the antimyotonic activity in vivo 104
The chemosensitizing agent lubeluzole binds calmodulin and inhibits Ca2+/calmodulin-dependent Kinase II 103
Preparation of (–)-(R)-2-(2,3,4,5,6-pentafluorophenoxy)-2-(phenyl-d5)acetic acid: an efficient 1H NMR chiral solvating agent for direct enantiomeric purity evaluation of quinoline-containing antimalarial drugs 102
2,6-xilididi e b-2,6,-xililossietilammine come ligandi anfipatici per i recettori benzodiazepinici di tipo mitocondriale 101
Searching for new antiarrhythmic agents: evaluation of meta-hydroxymexiletine enantiomers 101
(S)-ethyl 2-(tert-butoxycarbonylamino)-3-(2-iodo-4,5-methylenedioxyphenyl)propanoate 101
Recent trends in the discovery of small molecule blockers of sodium channels 99
Facile entry to (-)-R- and (+)-(S)-mexiletine 97
N-(Phenoxyalkyl)amides as MT1 and MT2 ligands: Antioxidant properties and inhibition of Ca2+/CaM-dependent kinase II 97
Inhibition of hERG potassium channel by the antiarrhythmic agent mexiletine and its metabolite m-hydroxymexiletine 95
Pharmacological differences between R(-) and S(+) Tocainide 93
The effects of tocainide and its chiral analogs on sodium channels of human muscle 92
The practice of medicinal chemistry 92
Hydroxylated analogs of mexiletine as tools for structural-requirements investigation of the sodium channel blocking activity 92
Inhibition of voltage-gated sodium channels by sumatriptan bioisosteres 91
Capillary zone electrophoresis for separation and quantitative determination of mexiletine and its main phase i metabolites 91
null 90
Microwave-assisted synthesis of KN-93, a potent and selective inhibitor of Ca2+/calmoduline-dependent protein kinase II 89
Old drug scaffold, new activity: Thalidomide-correlated compounds exert different effects on breast cancer cell growth and progression 89
Trivial, common, and systematic chemical names 87
Pharmacological differences between R(-) and S(+) Tocainide 87
Le applicazioni della chimica farmaceutica 87
Enzymatic Resolution of α-Methyleneparaconic Acids and Evaluation of their Biological Activity 87
2-Arylazetidines as ligands for nicotinic acetylcholine receptors 86
Facile routes for the preparation of 3,4-disubstituted 1,3-oxazolidines and 1,2,5-trisubstituted imidazolidin-4-ones 84
Stereoselective Modulation of P-Glycoprotein by Chiral Small Molecules 82
A Focus on the Synthesis and Pharmacokinetics of Tocainide and its Analogues 82
Fitocomplesso polifenolico standardizzato per la prevenzione delle patologie correlate all’esposizione da sostanze reattive dell’ossigeno e relativo metodo di produzione 82
Pharmacological differences between R(-) and S(+) tocainide 81
Chiral aryloxyalkylamines: selective 5-HT1B/1D activation and analgesic activity 81
Molecular determinants of state dependent block of voltage-gated sodium channels by pilsicainide 80
The therapeutic potential of rutin for diabetes: An update 80
Human ether-à-go-go-related potassium channel: exploring SAR to improve drug design 80
Stereospecific synthesis and absolute configuration of Mexiletine 79
New doxorubicin nanocarriers based on cyclodextrins 79
Microwave assisted synthesis of (±)-mandelic acid-d5, optical resolution, and absolute configuration determination 79
Optimization of microwave-assisted extraction of antioxidants from bamboo shoots of Phyllostachys pubescens 78
Ebola therapy: Developing new drugs or repurposing old ones? 77
Optically active mexiletine analogues as stereoselective blockers of voltage-gated Na+ channels 77
null 77
Facile, alternative route to Lubeluzole, its enantiomer, and the racemate 76
Synthesis, antiarrhythmic activity, and toxicological evaluation of mexiletine analogues 76
Design, synthesis, and pharmacological effects of structurally simple ligands for MT1 and MT2 melatonin receptors 75
null 75
Molecular Determinants of Human Voltage-Gated Sodium Channels Blockade by Lubeluzole 74
Inhibition of frog skeletal muscle sodium channels by newly synthesized chiral derivatives of mexiletine and tocainide 74
Pharmacological differences between R(-) and S(+) tocainide 73
One-step synthesis of homochiral O-aryl and O-heteroaryl mandelic acids and their use as efficient 1H NMR chiral solvating agents 73
New potent mexiletine and tocainide analogues evaluated in vivo and in vitro as antimyotonic agents on the myotonic ADR mouse 71
Antimyotonic effects of enantiomers of mexiletine-like drugs 71
Ligand efficiency metrics in drug discovery: the pros and cons from a practical perspective 71
Lubeluzole: from anti-ischemic to chemosensitizing agent 71
Comment on "in Situ Derivatization of (RS)-Mexiletine and Enantioseparation Using Micellar Liquid Chromatography: A Green Approach" 71
Optically active Mexiletine analogues as stereoselective blockers of voltage-gated Na+ channels 70
Stereospecific Synthesis of ‘‘para-Hydroxymexiletine’’ and Sodium Channel Blocking Activity Evaluation 70
Stereospecific synthesis of mexiletine and related compounds: Mitsunobu versus Williamson reaction 70
Molecular dissection of lubeluzole use-dependent block of voltage-gated sodium channels discloses new therapeutic potentials 70
Arilossialchilammine come ligandi per i recettori 5-HT1B/1D: Bioisosteria, chiralità e selettività 69
Phytochemical, Antioxidant and Anti-a-glucosidase Activity Evaluations of Bergenia cordifolia 69
Synthesis of new 2,6-prolylxylidide analogues of tocainide as stereoselective blockers of voltage-gated Na+ channels with increased potency and improved use-dependent activity 68
null 68
The trivial names of citrus limonoids 68
Did ebola survivors use plant medicines, and if so, which ones? 67
Molecular insights into the local anesthetic receptor within voltage-gated sodium channels using hydroxylated analogs of mexiletine 66
Activity of natural hydroxytyrosol versus a synthetic sample and its chiral analogues: hypothesis on mechanism of action. 65
Contribution to the study of 2-aryloxy-1-phenyl- and 2-aryloxy-2-phenylethanols. Differentiation by mass spectrometry 65
Dual action of mexiletine and its pyrroline derivatives as skeletal muscle sodium channel blockers and anti-oxidant compounds: Toward novel therapeutic potential 65
Nitro-substituted tetrahydroindolizines and homologs: Design, kinetics, and mechanism of α-glucosidase inhibition 65
Homologation of mexiletine alkyl chain and stereoselective blockade of skeletal muscle sodium channels 64
null 64
Analisi Farmaceutica 63
Stereoselectivity in central analgesic action of Tocainide and its analogs 63
Shouldn’t enantiomeric purity be included in the ‘minimum information about a bioactive entity’? 63
Discovery of a new mexiletine-derived agonist of the hERG K+channel 62
Facile Entry to Ethyl Tetrahydro-1H-pyrrolizin-7a(5H)-ylacetate: a Versatile Pharmaceutical Intermediate 62
Synthesis of (R)-, (S)-, and (RS)-hydroxymethylmexiletine one of the major metabolites of mexiletine 61
(2) Save to: more options Isosteric derivates of mexiletine: New potent use-dependent blockers of skeletal muscle sodium channels with potential antimyotonic activity 61
Synthesis and in vitro sodium channel blocking activity evaluation of novel homochiral mexiletine analogs 61
null 61
alpha-Glucosidase inhibitors: SAR studies on N-(aryloxyalkyl)phthalimides and their isosters 61
2-(9-Antryl)alcanoic acids as chloride channel modulators 60
Molecular Insights into hERG Potassium Channel Blockade by Lubeluzole 60
An improved synthesis of m-hydroxymexiletine, a potent mexiletine metabolite 60
Antioxidant activity of Uva di Troia ad acino piccolo: comparison of different extraction methods 58
Therapeutic effects of tocainide and mexiletine analogs on myotonic MTO and ADR mice 58
Newly synthesized mexiletine and tocainide analogues are potent use-dependent blockers of skeletal muscle sodium channels: potential implication for antimyotonic activity 58
Preclinical in vitro and in vivo evaluation of sodium channel blockers as possible alternative to mexiletine in the treatment of myotonia 57
Analoghi chirali della Tocainide: attività analgesica centrale 57
Substituted prolinammidic biphenyltetrazoles as new AT1 receptor antagonists 56
Hydroxylation on the aromatic ring of mexiletine affects the block of voltage-gated sodium channels 56
null 56
Totale 7.882
Categoria #
all - tutte 58.814
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 58.814


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191.037 0 0 0 0 0 0 0 0 0 189 388 460
2019/20203.623 726 266 80 257 375 182 388 224 466 170 418 71
2020/20212.736 452 108 258 142 285 111 231 131 285 374 208 151
2021/20221.990 89 333 36 96 48 100 71 98 115 118 309 577
2022/20233.325 546 289 174 306 432 444 32 397 525 24 86 70
2023/20241.001 94 233 54 102 70 287 35 76 36 14 0 0
Totale 15.472